Literature DB >> 31634779

Clinical and biological significances of heat shock protein 90 (Hsp90) in human nasopharyngeal carcinoma cells and anti-cancer effects of Hsp90 inhibitor.

Fangxian Liu1, Liangliang Wang1, Shijiang Yi1, Qianghe Liu1, Xiaoxiao Xu2, Min Su3.   

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor in South China, characterized with high death rate. If untreated, NPC cells will be invasiveness and then spread to other tissues. In clinical practice, however, lack of early effective screening to prevent the NPC development. Therefore, candidate biomarker for detecting NPC is developing urgently. In current study, human NPC data and samples were collected for tests, followed by cell culture study. As results, Epstein-Barr virus (EBV)-based human NPC sections showed increased expressions of heat shock protein 90 (Hsp90), protein kinase B (AKT), and Hsp90 levels were positively expressed than those in cytokeratin 19 (CK19). The clinical data showed unchanged contents of blood cancer markers. In cell line study, Hsp90-treated cells (CNE1, 5-8 F) resulted in promoted cellular growth and proliferation. Additionally, proliferative proteins of cellular extracellular regulated protein kinase (Erk1/2), phospho-Erk1/2 (Thr202+Tyr204), B-cell lymphoma-2 (Bcl-2), AKT, phospho-AKT (Ser473), Ki-67 were up-regulated in Hsp90 treatments, while the apoptotic protease activating factor-1 (Apaf1) were down-regulated. Followed by treatment with Hsp90 inhibitor, the NPC cells exhibited inhibited cellular proliferation and growth, induced cell apoptosis, reduced proliferative proteins of Erk1/2, phospho-Erk1/2 (Thr202+Tyr204), AKT, phospho-AKT (Ser473), Bcl-2, Ki-67, and elevated Apaf1 expression. In conclusion, the current findings obtained from this study demonstrate that Hsp90 effectively promotes cell proliferation through activating carcinomatous ERK1/2, phospho-Erk1/2 (Thr202+Tyr204), AKT, phospho-AKT (Ser473) expressions in NPC cells. Briefly, Hsp90 may be a promising biomarker to screen NPC, including early stage.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Heat shock protein 90; Inhibitor; Marker; Nasopharyngeal carcinoma; Proliferation

Mesh:

Substances:

Year:  2019        PMID: 31634779     DOI: 10.1016/j.biopha.2019.109533

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Comprehensive analysis of key genes associated with ceRNA networks in nasopharyngeal carcinoma based on bioinformatics analysis.

Authors:  Yuanji Xu; Xinyi Huang; Wangzhong Ye; Yangfan Zhang; Changkun Li; Penggang Bai; Zhizhong Lin; Chuanben Chen
Journal:  Cancer Cell Int       Date:  2020-08-26       Impact factor: 5.722

Review 2.  Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.

Authors:  Ping Liu; Ji Xiao; Yiliang Wang; Xiaowei Song; Lianzhou Huang; Zhe Ren; Kaio Kitazato; Yifei Wang
Journal:  Mol Med       Date:  2021-09-16       Impact factor: 6.354

3.  Anti-Cancer Properties of Ginkgolic Acids in Human Nasopharyngeal Carcinoma CNE-2Z Cells via Inhibition of Heat Shock Protein 90.

Authors:  Hong-Mei Li; Hui Ma; Xiaolong Sun; Bohan Li; Chengjiang Cao; Yiqun Dai; Meilin Zhu; Cheng-Zhu Wu
Journal:  Molecules       Date:  2021-10-30       Impact factor: 4.411

4.  Plasma Levels of Heat Shock Protein 90 Alpha Associated With Colorectal Cancer Development.

Authors:  Wene Wei; Jiahui Zhou; Lipeng Chen; Haizhou Liu; Fuyong Zhang; Jilin Li; Shufang Ning; Shirong Li; Chen Wang; Yi Huang; Chang Zou; Litu Zhang
Journal:  Front Mol Biosci       Date:  2021-07-08

5.  Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma.

Authors:  Qian Ye; Junying Guo; Yansong Chen; Zhaolei Cui; Yan Chen
Journal:  Cancer Manag Res       Date:  2021-07-20       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.